RSI and iRIS are mutually related to improved outcomes in patients treated with radiation. (A) Tumors were separated into quadrants by RSIlo and RSIhi (population median RSI, 0.42), as well as iRISlo and iRIShi (population median iRIS, 3.61) and represented on the TIES map. (B) Tumor types were classified based on the proportion of patients in the most ‘favorable’ quadrant (e.g., iRISlo/RSIlo). (C) Patient NSCLC tumors with dual RSIlo/iRISlo phenotypes have improved OS (HR 0.38, 95% CI: 0.16–0.92; P < 0.01) compared to those with RSIhi/iRIShi. (D) A RSIlo phenotype with an unfavorable TIES (iRIShi) or vice versa, cannot compensate for the other (HR 1.1, 95% CI: 0.4–3.1; P = 0.84).